Leonidas Apostolidis1,2, Jan Pfeiffenberger3,2, Daniel Gotthardt3,2, Boris Radeleff4,2, Arianeb Mehrabi5,2, Peter Schemmer5,6,2, Dirk Jäger1,2, Peter Schirmacher7,2, Wolfgang Stremmel3,2, Henning Schulze-Bergkamen1,8,2, Christoph Springfeld1,2, Karl Heinz Weiss3,2. 1. Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. 2. Liver Cancer Center Heidelberg, Heidelberg, Germany. 3. Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany. 4. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany. 5. Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany. 6. Department of Surgery, Medical University of Graz, Graz, Austria. 7. Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 8. Department of Internal Medicine 2, St. Mary Hospital, Wesel, Germany.
Abstract
BACKGROUND/AIM: Sorafenib leads to improved survival in advanced hepatocellular carcinoma (HCC) patients. Continuation of sorafenib beyond progression has been a possible treatment strategy when further approved therapeutic agents are lacking. METHODS: We performed a retrospective analysis of all HCC patients at our institution with documented disease progression under treatment with sorafenib. Overall survival (OS) from start of sorafenib treatment was compared between patients who received sorafenib for > 3 weeks beyond progression (group 1) and those who discontinued sorafenib ≤3 weeks after progression (group 2). Group 1 was further subdivided into those patients who received sorafenib for > 3 months (group 1a) and those who received it for ≤3 months (group 1b). RESULTS: A total of 71 patients were analyzed. Median OS for all patients was 15.4 months. OS in group 1 (15.6 months) and 2 (13.0 months) was similar (p = 0.90). Patients in group 1a showed significantly prolonged median OS (19.7 months) compared to that of patients in group 1b (13.6 months, p = 0.004), and they showed a trend towards prolonged OS compared to group 2 (p = 0.126). For patients with a poor prognosis according to their Child-Pugh stage, performance status, alpha-fetoprotein, and response to prior sorafenib treatment, OS was significantly prolonged in group 1 versus group 2 (12.1 vs. 6.4 months, p = 0.019). CONCLUSION: In HCC patients, continuing sorafenib beyond progression for > 3 months is associated with improved survival compared to discontinuing sorafenib within 3 months. Furthermore, patients with a poor prognosis who continue sorafenib beyond progression in general show significantly prolonged survival.
BACKGROUND/AIM: Sorafenib leads to improved survival in advanced hepatocellular carcinoma (HCC) patients. Continuation of sorafenib beyond progression has been a possible treatment strategy when further approved therapeutic agents are lacking. METHODS: We performed a retrospective analysis of all HCC patients at our institution with documented disease progression under treatment with sorafenib. Overall survival (OS) from start of sorafenib treatment was compared between patients who received sorafenib for > 3 weeks beyond progression (group 1) and those who discontinued sorafenib ≤3 weeks after progression (group 2). Group 1 was further subdivided into those patients who received sorafenib for > 3 months (group 1a) and those who received it for ≤3 months (group 1b). RESULTS: A total of 71 patients were analyzed. Median OS for all patients was 15.4 months. OS in group 1 (15.6 months) and 2 (13.0 months) was similar (p = 0.90). Patients in group 1a showed significantly prolonged median OS (19.7 months) compared to that of patients in group 1b (13.6 months, p = 0.004), and they showed a trend towards prolonged OS compared to group 2 (p = 0.126). For patients with a poor prognosis according to their Child-Pugh stage, performance status, alpha-fetoprotein, and response to prior sorafenib treatment, OS was significantly prolonged in group 1 versus group 2 (12.1 vs. 6.4 months, p = 0.019). CONCLUSION: In HCC patients, continuing sorafenib beyond progression for > 3 months is associated with improved survival compared to discontinuing sorafenib within 3 months. Furthermore, patients with a poor prognosis who continue sorafenib beyond progression in general show significantly prolonged survival.
Authors: Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka Journal: Lancet Oncol Date: 2012-11-16 Impact factor: 41.316
Authors: Jamie E Chaft; Geoffrey R Oxnard; Camelia S Sima; Mark G Kris; Vincent A Miller; Gregory J Riely Journal: Clin Cancer Res Date: 2011-08-19 Impact factor: 12.531
Authors: Axel Grothey; Mary M Sugrue; David M Purdie; Wei Dong; Daniel Sargent; Eric Hedrick; Mark Kozloff Journal: J Clin Oncol Date: 2008-10-14 Impact factor: 44.544
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta Journal: Lancet Oncol Date: 2012-11-20 Impact factor: 41.316